Form 4: NHC Director Exercises Stock Options
Insider Transaction Report
National Healthcare Corp Director Robert G. Adams exercised 4,500 stock options at $71.64 per share.
Summary
- Robert G. Adams, a Director of National Healthcare Corp (NHC), executed a transaction on September 19, 2025.
- The transaction involved the exercise of 4,500 stock options from a 2021 grant, which were part of the 2020 Omnibus Equity Incentive Plan.
- The exercise price for these options was $71.64 per share.
- Following the exercise, Mr. Adams' direct beneficial ownership of the 2021 grant options is now 0.
- His indirect beneficial ownership of common stock includes 430,341 shares through a partnership and 13,579 shares through a trust.
- He continues to hold 7,500 options each from the 2022, 2023, 2024, and 2025 grants, with varying exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: A neutral score as Form 4 filings are factual disclosures of insider transactions and do not inherently convey positive or negative sentiment about the company's performance or outlook. The exercise of options is a routine event for executives.
Positives
- Director Robert G. Adams exercised 4,500 stock options, converting potential equity into actual shares, which can align his interests further with shareholders.
- The grant and exercise of these stock options are exempt from Section 16(b) pursuant to Rule 16b-3(d), indicating compliance with regulatory requirements.
Future Outlook
The filing does not contain forward-looking statements or guidance, as it is a disclosure of a past insider transaction.
Industry Context
This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: The exercise of stock options by a director can be seen as a routine event, potentially increasing the director's alignment with shareholder interests through increased direct equity ownership.
Key Dates
| Date | Description |
|---|---|
| 05/06/2021 | Date of grant for the exercised stock options (2020 Omnibus Equity Incentive Plan). |
| 05/06/2022 | Date exercisable for the 2021 stock option grant. |
| 05/05/2023 | Date exercisable for the 2022 stock option grant. |
| 05/04/2024 | Date exercisable for the 2023 stock option grant. |
| 05/09/2025 | Date exercisable for the 2024 stock option grant. |
| 09/19/2025 | Date of stock option exercise transaction. |
| 09/22/2025 | Signature date of the reporting person for the Form 4 filing. |
| 05/05/2026 | Expiration date for the 2021 stock option grant. |
| 05/08/2026 | Date exercisable for the 2025 stock option grant. |
| 05/04/2027 | Expiration date for the 2022 stock option grant. |
| 05/03/2028 | Expiration date for the 2023 stock option grant. |
| 05/08/2029 | Expiration date for the 2024 stock option grant. |
| 05/07/2030 | Expiration date for the 2025 stock option grant. |
Recommendation
holdThis Form 4 filing reports a routine insider transaction where a director exercised stock options. It does not provide new information regarding the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The exercise of options is a common event for executives and typically does not signal a significant shift in company prospects. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific transaction.
Keywords
National Healthcare Corp, NHC, Robert G. Adams, stock options, insider transaction, Form 4, equity incentive plan, director, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.